Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.
A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aripiprazole | The metabolism of Aripiprazole can be increased when combined with Pentobarbital. |
| Buprenorphine | Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital. |
| Magnesium sulfate | The therapeutic efficacy of Pentobarbital can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Pentobarbital may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital. |
| Mirtazapine | Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital. |
| Orphenadrine | Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Pramipexole | Pentobarbital may increase the sedative activities of Pramipexole. |
| Ropinirole | Pentobarbital may increase the sedative activities of Ropinirole. |
| Rotigotine | Pentobarbital may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Pentobarbital. |
| Suvorexant | Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital. |
| Thalidomide | Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Dabrafenib | The serum concentration of Pentobarbital can be decreased when it is combined with Dabrafenib. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Pentobarbital. |
| Luliconazole | The serum concentration of Pentobarbital can be increased when it is combined with Luliconazole. |
| Mefloquine | The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Mefloquine. |
| Orlistat | Orlistat can cause a decrease in the absorption of Pentobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chloramphenicol | The metabolism of Pentobarbital can be decreased when combined with Chloramphenicol. |
| Doxycycline | The serum concentration of Doxycycline can be decreased when it is combined with Pentobarbital. |
| Felbamate | The serum concentration of Pentobarbital can be increased when it is combined with Felbamate. |
| Griseofulvin | The serum concentration of Griseofulvin can be decreased when it is combined with Pentobarbital. |
| Lamotrigine | The serum concentration of Lamotrigine can be decreased when it is combined with Pentobarbital. |
| Mianserin | The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Mianserin. |
| Primidone | The risk or severity of adverse effects can be increased when Primidone is combined with Pentobarbital. |
| Methylphenobarbital | The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pentobarbital. |
| Phenobarbital | The risk or severity of adverse effects can be increased when Phenobarbital is combined with Pentobarbital. |
| Pyridoxine | The metabolism of Pentobarbital can be increased when combined with Pyridoxine. |
| Teniposide | The serum concentration of Teniposide can be decreased when it is combined with Pentobarbital. |
| Voriconazole | The serum concentration of Voriconazole can be decreased when it is combined with Pentobarbital. |
| Topotecan | Pentobarbital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Pentobarbital. |
| Sodium oxybate | Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Ifosfamide | The metabolism of Ifosfamide can be increased when combined with Pentobarbital. |
| Perampanel | The metabolism of Perampanel can be increased when combined with Pentobarbital. |
| Warfarin | The metabolism of Warfarin can be increased when combined with Pentobarbital. |
| Acenocoumarol | The metabolism of Acenocoumarol can be increased when combined with Pentobarbital. |
| (R)-warfarin | The metabolism of (R)-warfarin can be increased when combined with Pentobarbital. |
| R,S-Warfarin alcohol | The metabolism of R,S-Warfarin alcohol can be increased when combined with Pentobarbital. |
| S,R-Warfarin alcohol | The metabolism of S,R-Warfarin alcohol can be increased when combined with Pentobarbital. |
| (S)-Warfarin | The metabolism of (S)-Warfarin can be increased when combined with Pentobarbital. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Pentobarbital. |
| Aminophylline | The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Aminophylline. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Botulinum toxin type A. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Botulinum toxin type B. |
| Meperidine | Pentobarbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine. |
| Somatostatin | The risk or severity of adverse effects can be increased when Somatostatin is combined with Pentobarbital. |
| Ethanol | Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital. |
| Zimelidine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Zimelidine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Seproxetine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Alaproclate. |
| Duloxetine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Duloxetine. |
| Naltrexone | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Bezitramide. |
| Butorphanol | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Butorphanol. |
| Pentazocine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Pentazocine. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Diphenoxylate. |
| Dezocine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Dezocine. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Diamorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Carfentanil. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Dihydromorphine. |
| DPDPE | The risk or severity of adverse effects can be increased when Pentobarbital is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Lofentanil. |
| Normethadone | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Nicomorphine. |
| Meptazinol | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Carfentanil, C-11. |
| Alfentanil | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Fentanyl. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Levacetylmethadol. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Benzhydrocodone. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Hydromorphone. |
| Morphine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Codeine. |